Background: Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is a rare X-linked disorder caused by deficiency of iduronate-2-sulfatase (I2S) enzyme, which leads to the accumulation of partially digested glycosaminoglycans (GAGs) in the lysosomes and induces multisystemic alteration (coarse facial features; skeletal dysplasia; hepatosplenomegaly; joint stiffness and contractures; heart, lung, vision, and hearing disability; profound neurological decline).
The purpose of this study is to present the clinical and genetic characteristics of Romanian patients with Hunter syndrome and the genotype–phenotype correlation.
Material and Methods: 15 unrelated patients, with MPS II ranging from mild (4 subjects) to severe phenotype (11 subjects) aged 2 to 20 years, were evaluated clinically, cognitive development, enzyme assay and molecular analysis.
Results: The molecular analysis of the 15 unrelated Romanian MPS II patients has identified 15 different mutations (2 major genetic defects (13%) and 13 minor genetic defects (87%)): microdeletions and point mutations (missense, nonsense), seven of them described for the first time—deletion encompassing 3 to exon 7; c823G>T, pD275Y; c.1600A>C (pN534H); c.102_10delAG (p.D5Cfs*11); c.448_471del (p.P150_P157del); c.421delA (p.I141Yfs*72); and c.419-1G>C. The major genetic defects were correlated with a severe course of disease.
Conclusion: This is the first study on the clinical and molecular characterization of the MPS II Romanian patients. This study supports the evidence of the mutational heterogeneity of the I2S gene as well as the difficulty to correlate genotype and phenotype in the patients with MPS II.
Hunter disease Mucopolysaccharidosis type II Romania
Beck M (2011) Mucopolysaccharidosis type II (Hunter syndrome): clinical picture and treatment. Curr Pharm Biotechnol 12:861–866CrossRefPubMedGoogle Scholar
Bonuccelli G, Regis S, Filocamo M et al (1998) A deletion involving exons 2–4 in the iduronate-2-sulfatase gene of a patient with intermediate Hunter syndrome. Clin Genet 53:474–477CrossRefPubMedGoogle Scholar
Brusius-Facchin AC, Schwartz IVD, Zimmer C et al (2014) Mucopolysaccharidosis type II: Identification of 30 novel mutations among Latin American patients. Mol Genet Metab 111:133–138CrossRefPubMedGoogle Scholar
Bunge S, Steglich C, Beck M et al (1992) Mutation analysis of the iduronate-2-sulfatase gene in patients with mucopolysaccharidosis type II (Hunter syndrome). Hum Mol Genet 1:335–339CrossRefPubMedGoogle Scholar
Bunge S, Steglich C, Zuther C et al (1993) Iduronate-2-sulfatase gene mutations in 16 patients with mucopolysaccharidosis type II (Hunter syndrome). Hum Mol Genet 2:1871–1875CrossRefPubMedGoogle Scholar
Crotty PL, Braun SE, Anderson RA et al (1992) Mutation R468W of the iduronate-2-sulfatase gene in mild Hunter syndrome (mucopolysaccharidosis type II) confirmed by in vitro mutagenesis and expression. Hum Mol Genet 1(9):755–757CrossRefPubMedGoogle Scholar
Flomen RH, Green PM, Bentley DR et al (1992) Detection of point mutations and a gross deletion in six Hunter syndrome patients. Genomics 13:543–550CrossRefPubMedGoogle Scholar
Froissart R, Blond JL, Maire I et al (1993) Hunter syndrome: gene deletions and rearrangements. Hum Mutat 2:138–140CrossRefPubMedGoogle Scholar
Froissart R, Maire I, Millat G et al (1998) Identification of iduronate sulfatase gene alterations in 70 unrelated Hunter patients. Clin Genet 53:362–368CrossRefPubMedGoogle Scholar
Giugliani R, Villarreal ML, Valdez CA et al (2014) Guidelines for diagnosis and treatment of Hunter syndrome for clinicians in Latin America. Genet Mol Biol 37:315–329CrossRefPubMedPubMedCentralGoogle Scholar
Goldenfum SL, Young E, Michelakakis H et al (1996) Mutation analysis in 20 patients with Hunter disease. Hum Mutat 7:76–78CrossRefPubMedGoogle Scholar
Gort L, Chabás A, Coll MJ (1998) Hunter disease in the Spanish population: molecular analysis in 31 families. J Inherit Metab Dis 21(6):655–661CrossRefPubMedGoogle Scholar
Hartog C, Fryer A, Upadhyaya M (1999) Mutation analysis of iduronate-2-sulphatase gene in 24 patients with Hunter syndrome: characterisation of 6 novel mutations. Hum Mutat 14(1):87CrossRefPubMedGoogle Scholar
Karsten SL, Voskoboeva E, Tishkanina S et al (1998) Mutational spectrum of the iduronate-2-sulfatase (IDS) gene in 36 unrelated Russian MPS II patients. Hum Genet 103(6):732–735CrossRefPubMedGoogle Scholar
Lissens W, Seneca S, Liebaers I (1997) Molecular analysis in 23 Hunter disease families. J Inherit Metab Dis 20(3):453–456CrossRefPubMedGoogle Scholar
Lualdi S, Di Rocco M, Corsolini F et al (2006) Identification of nine new IDS alleles in mucopolysaccharidosis II. Quantitative evaluation by real-time RT-PCR of mRNAs sensitive to nonsense-mediated and nonstop decay mechanisms. Biochim Biophys Acta 1762(4):478–484CrossRefPubMedGoogle Scholar
Martin R, Beck M, Eng C et al (2008) Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 121(2):377–386CrossRefGoogle Scholar
Patlas M, Hadas-Halpern I, Abrahamov A, Zimran A, Elstein D (2002) Repeat abdominal ultrasound evaluation of 100 patients with type I Gaucher disease treated with enzyme replacement therapy for up to 7 years. Hematol J 3:17–20CrossRefPubMedGoogle Scholar
Rathmann M, Bunge S, Beck M, Kresse H, Tylki-Szymanska A, Gal A (1996) Mucopolysaccharidosis type II (Hunter syndrome): mutation “hot spots” in the iduronate-2-sulfatase gene. Am J Hum Genet 59(6):1202–1209PubMedPubMedCentralGoogle Scholar
Scarpa M, Almássy Z, Beck M et al (2011) Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis 6(1):72CrossRefPubMedPubMedCentralGoogle Scholar
Timms KM, Lu F, Shen Y et al (1995) 130 kb of DNA sequence reveals two new genes and a regional duplication distal to the human iduronate-2-sulfate sulfatase locus. Genome Res 5(1):71–78CrossRefPubMedGoogle Scholar
Weinreb NJ, Charrow J, Andersson HC et al (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 113:112–119CrossRefPubMedGoogle Scholar
Wraith JE, Scarpa M, Beck M et al (2008) Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167(3):267–277CrossRefPubMedGoogle Scholar